EE200000729A - Neuroosivastane kompositsioon hirmuseisunditest või depressioonist tingitud neurootiliste ning käitumuslike muutuste ennetamiseks ja/või raviks - Google Patents

Neuroosivastane kompositsioon hirmuseisunditest või depressioonist tingitud neurootiliste ning käitumuslike muutuste ennetamiseks ja/või raviks

Info

Publication number
EE200000729A
EE200000729A EEP200000729A EEP200000729A EE200000729A EE 200000729 A EE200000729 A EE 200000729A EE P200000729 A EEP200000729 A EE P200000729A EE P200000729 A EEP200000729 A EE P200000729A EE 200000729 A EE200000729 A EE 200000729A
Authority
EE
Estonia
Prior art keywords
neurotic
composition
depression
treating
anxiety
Prior art date
Application number
EEP200000729A
Other languages
English (en)
Estonian (et)
Inventor
Cavazza Claudio
Original Assignee
Sigma-Tau Healthscience S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Healthscience S.P.A. filed Critical Sigma-Tau Healthscience S.P.A.
Publication of EE200000729A publication Critical patent/EE200000729A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200000729A 1998-06-25 1999-06-17 Neuroosivastane kompositsioon hirmuseisunditest või depressioonist tingitud neurootiliste ning käitumuslike muutuste ennetamiseks ja/või raviks EE200000729A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000425A IT1299195B1 (it) 1998-06-25 1998-06-25 Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
PCT/IT1999/000175 WO1999066914A2 (en) 1998-06-25 1999-06-17 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin

Publications (1)

Publication Number Publication Date
EE200000729A true EE200000729A (et) 2002-06-17

Family

ID=11406010

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000729A EE200000729A (et) 1998-06-25 1999-06-17 Neuroosivastane kompositsioon hirmuseisunditest või depressioonist tingitud neurootiliste ning käitumuslike muutuste ennetamiseks ja/või raviks

Country Status (26)

Country Link
US (1) US6346282B1 (no)
EP (1) EP1089744B1 (no)
JP (1) JP2002518438A (no)
KR (1) KR20010053059A (no)
CN (1) CN1307479A (no)
AT (1) ATE228369T1 (no)
AU (1) AU756542B2 (no)
BR (1) BR9912179A (no)
CA (1) CA2334858C (no)
DE (1) DE69904173T2 (no)
DK (1) DK1089744T3 (no)
EE (1) EE200000729A (no)
ES (1) ES2188178T3 (no)
HU (1) HUP0102546A3 (no)
IL (1) IL140159A0 (no)
IS (1) IS5765A (no)
IT (1) IT1299195B1 (no)
MA (1) MA26651A1 (no)
NO (1) NO20006430L (no)
NZ (1) NZ508882A (no)
PL (1) PL194177B1 (no)
PT (1) PT1089744E (no)
SK (1) SK19302000A3 (no)
TN (1) TNSN99135A1 (no)
TR (1) TR200003736T2 (no)
WO (1) WO1999066914A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
DE10015617A1 (de) * 2000-03-29 2001-10-04 Peter Laetzsch Migränemittel
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
IT1317035B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
ATE437884T1 (de) * 2003-05-29 2009-08-15 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
EP1854486A3 (de) * 2006-03-14 2010-06-02 Wilfried P. Bieger Verwendung von Neurotransmitter-Derivaten zur Herstellung von Mitteln zur Behandlung von neuroendokrinen gesundheitlichen Störungen
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
AU2009315771A1 (en) * 2008-11-11 2010-05-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
BRPI0900614A2 (pt) 2009-02-13 2011-06-28 Univ Fed Do Rio Grande Do Sul Ufrgs extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção
SG185692A1 (en) * 2010-06-16 2013-01-30 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
CA2807510A1 (en) 2010-08-05 2012-02-09 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
JP2014145857A (ja) 2013-01-28 2014-08-14 Sony Corp 表示装置およびその製造方法、並びに電子機器
EA201700348A1 (ru) * 2015-02-04 2018-02-28 Общество С Ограниченной Ответственностью "Консорциум-Пик" Способ повышения эффективности терапии антидепрессантом в комплексной антидепрессивной терапии и фармацевтическая комбинация

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
DE4239959A1 (de) * 1992-11-27 1994-06-01 Schwabe Willmar Gmbh & Co Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia

Also Published As

Publication number Publication date
PT1089744E (pt) 2003-04-30
IT1299195B1 (it) 2000-02-29
HUP0102546A2 (hu) 2001-10-28
DE69904173T2 (de) 2003-08-28
WO1999066914A3 (en) 2000-04-06
TNSN99135A1 (fr) 2005-11-10
NZ508882A (en) 2002-06-28
SK19302000A3 (sk) 2001-09-11
TR200003736T2 (tr) 2001-06-21
KR20010053059A (ko) 2001-06-25
NO20006430D0 (no) 2000-12-15
ES2188178T3 (es) 2003-06-16
DK1089744T3 (da) 2003-03-24
AU4391099A (en) 2000-01-10
CA2334858A1 (en) 1999-12-29
EP1089744A2 (en) 2001-04-11
CN1307479A (zh) 2001-08-08
CA2334858C (en) 2010-08-24
HUP0102546A3 (en) 2003-08-28
IL140159A0 (en) 2002-02-10
ATE228369T1 (de) 2002-12-15
JP2002518438A (ja) 2002-06-25
NO20006430L (no) 2001-02-21
AU756542B2 (en) 2003-01-16
IS5765A (is) 2000-12-08
ITRM980425A0 (it) 1998-06-25
PL345279A1 (en) 2001-12-03
EP1089744B1 (en) 2002-11-27
WO1999066914A2 (en) 1999-12-29
DE69904173D1 (de) 2003-01-09
ITRM980425A1 (it) 1999-12-25
BR9912179A (pt) 2001-04-10
MA26651A1 (fr) 2004-12-20
US6346282B1 (en) 2002-02-12
PL194177B1 (pl) 2007-05-31

Similar Documents

Publication Publication Date Title
EE200000729A (et) Neuroosivastane kompositsioon hirmuseisunditest või depressioonist tingitud neurootiliste ning käitumuslike muutuste ennetamiseks ja/või raviks
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
ATE297731T1 (de) Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
LT2004060A (en) A composition for treating neurocerebrovascular disorders
ES2118686T3 (es) Extracto estable de hypericum perforatum l., proceso para su preparacion y composiciones farmaceuticas.
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
ATE283032T1 (de) Formulierungen und verfahren zur verminderung von hautirritationen
ATE525061T1 (de) Feste selbst-haftende zusammensetzungen zur topischen behandlung von störungen der mundschleimhaut
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE69937564D1 (de) Prostata- formulierung
EA199900796A1 (ru) Стабильный экстракт зверобоя, способ его приготовления и фармацевтические составы на его основе
DK0847755T3 (da) Anvendelse af en ekstrakt af cimicifuga racemosa
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
BR0205473A (pt) Composição cosmética ou dermatológica de uso tópico, uso de uma composição, processo para melhorar a estabilidade de pelo menos um derivado do dibenzoilmetano e uso de um derivado de 2-hidroxibenzofenona amino-substituìdo
DE69123363D1 (de) Neue zusammensetzungen
BR0205475A (pt) Composição cosmética ou dermatológica de uso tópico, uso de uma composição, uso de um derivado de 2-hidroxibenzofenona amino-substituìdo e processo para melhorar a estabilidade de um derivado de 1,3,5 triazina fotossensìvel em presença de um derivado de dibenzoilmetano
DE59900222D1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
BR9911897B1 (pt) composição de perfume, produto desodorante, e, processo de cosmético para a redução ou prevenção do mau cheiro do corpo.
DE69707121D1 (de) Neue vitamin-d-analoga
BR0005010A (pt) Composição para tratamento de distúrbios de secreção externa exceto a hipolacrimação e seu uso
AR004006A1 (es) Extracto estable de hypericum perforatum l, metodo para su preparacion y composiciones farmaceuticas que lo contienen
DE69921058D1 (de) Verwendung von Triclosan zur Behandlung und Prävention von Mukositis
DE60107516D1 (de) Verwendung von Pregabalin zur Asthma Behandlung